Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 214 Results

March 1, 2023

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

December 28, 2022

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

November 9, 2022

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

November 2, 2022

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

October 17, 2022

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

September 9, 2022

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

August 22, 2022

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

August 9, 2022

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

May 4, 2022

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

April 7, 2022

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

«...2 345 6...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top